A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT07192471

Public ClinicalTrials.gov record NCT07192471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Open-label, Non-randomized, Dose-escalation and Backfill Study of KK2223 in Participants With Relapsed or Refractory T-cell Non Hodgkin Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

Study identification

NCT ID: NCT07192471
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Kyowa Kirin, Inc.; Industry
Enrollment: 72 participants

Conditions and interventions

Conditions

T-cell NHL (PTCL or CTCL)

Interventions

KK2223 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2026
Primary completion: Feb 28, 2029
Completion: Aug 31, 2030
Last update posted: Aug 20, 2026

2026 – 2030

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Not yet recruiting
University of California, Irvine Medical Center - Hematology/Oncology	Orange	California	92868	Not yet recruiting
Stanford University School of Medicine	Stanford	California	94305	Recruiting
Moffit Cancer Center	Tampa	Florida	33612	Not yet recruiting
Emory University Medical Center	Atlanta	Georgia	30322	Not yet recruiting
University of Iowa Health	Iowa City	Iowa	52242	Not yet recruiting
Beth Israel Deaconess Medical Center - Research	Boston	Massachusetts	02215	Not yet recruiting
Washington University School of Medicine - Oncology Hospital - Public	St Louis	Missouri	63110	Recruiting
Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division	Hackensack	New Jersey	07601-2105	Not yet recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10021-6007	Recruiting
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	Not yet recruiting
Oregon Health & Science University	Portland	Oregon	97239	Not yet recruiting
University of Pennsylvania - Abramson Cancer Center	Philadelphia	Pennsylvania	19104	Not yet recruiting
The University of Texas - MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07192471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2026 · Synced Sep 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07192471 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →